Catheter Port Reversal in Citrate Continuous Veno-Venous Hemofiltration

被引:3
|
作者
Boer, Willem [1 ]
Van Tornout, Mathias [2 ]
Vander Laenen, Margot [1 ]
Engelen, Kim [1 ]
Meex, Ingrid [1 ]
Jorens, Philippe [3 ]
机构
[1] Ziekenhuis Oost Limburg ZOL, Dept Anesthesiol Intens Care Med Emergency Med &, Schiepsebos 6, B-3600 Genk, Belgium
[2] AZ Sint Jan Brugge Oostende AV, Dept Anesthesiol & Intens Care Med, Brugge, Belgium
[3] Univ Antwerp, Antwerp Univ Hosp, Dept Crit Care Med, LEMP, Edegem, Belgium
来源
KIDNEY INTERNATIONAL REPORTS | 2021年 / 6卷 / 11期
关键词
access recirculation; catheter dysfunction; continuous renal replacement therapy; regional citrate anticoagulation; ACCESS RECIRCULATION; HEMODIALYSIS;
D O I
10.1016/j.ekir.2021.08.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Knowledge of effects of catheter port reversal (CathPR), when blood is withdrawn from the venous port and returned via the arterial port, often used in dysfunctional catheters in renal replacement therapy, is limited in the setting of citrate continuous veno-venous hemofiltration (CVVH). Methods: In this open trial, post-filter ionized calcium (PfiCa), post-filter citrate concentration (PfCC), catheter recirculation, and solute clearance were measured before, during, and after 6 hours of CathPR, in well-functioning catheters. All other settings, including citrate settings, were left constant during the study. Results: Twenty-three patients were included. Mean PfiCa before CathPR of 0.36 mmol/L (SD 0.06) decreased to 0.31 (0.04) after 2 hours (P = 0.002), 0.31 (0.04) (P = 0.002) at 4 hours, and 0.31 (0.04) at 6 hours (P = 0.001). Return to normal increased mean PfiCa to 0.34 (0.06) (P = 0.006). Mean PfCC rose from 592 mg/L (SD 164) before CathPR to 649 mg/L (190) after 2 hours (P = 0.045), to 696 mg/L (192) after 4 hours (P < 0.001), and to 657 mg/L (214) after 6 hours (P = 0.018). Return to normal decreased mean PfCC to 598 mg/L (184) (P = 0.024). Mean recirculation increased during CathPR (from 4.3% [0-8.7] before to 13.8% [9.7-22.2], P < 0.001). Urea, potassium, and creatinine clearances dropped significantly, but calcium clearance was unaffected. Conclusion: CathPR caused a significant decrease in PfiCA and increase in PfCC. Calcium handling differs from other solutes because of increases caused in citrate concentration and subsequent effects on calcium chelation. In citrate CVVH, CathPR in dysfunctional catheters should be limited in time, with intensive follow-up.
引用
收藏
页码:2775 / 2781
页数:7
相关论文
共 50 条
  • [41] Treatment of acute hypernatremia in severely burned patients using continuous veno-venous hemofiltration with gradient sodium replacement fluid: a report of nine cases
    Huang, Chen
    Zhang, Peng
    Du, Rui
    Li, Yangping
    Yu, Yan
    Zhou, Meilan
    Jing, Rui
    Li, Li
    Zheng, Yong
    Wang, Hanmin
    Liu, Hongbao
    He, Lijie
    Sun, Shiren
    INTENSIVE CARE MEDICINE, 2013, 39 (08) : 1495 - 1496
  • [42] Case Report: Monitoring Vancomycin Concentrations and Pharmacokinetic Parameters in Continuous Veno-Venous Hemofiltration Patients to Guide Individualized Dosage Regimens: A Case Analysis
    Chen, Jihui
    Huang, Xiaohui
    Lin, Zhiyan
    Li, Chao
    Ding, Haoshu
    Du, Junming
    Li, Lixia
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [43] A preliminary survey of bacterial contamination of the dialysate circuit in continuous veno-venous hemodialysis
    Kanagasundaram, NS
    Larive, AB
    Paganini, EP
    CLINICAL NEPHROLOGY, 2003, 59 (01) : 47 - 55
  • [44] Clinical Outcome Following the Use of Inadequate Solutions for Continuous Veno-Venous Hemodiofiltration
    Celik, Jale Bengi
    Topal, Ahmet
    Kartal, Elmas
    Yosunkaya, Alper
    RENAL FAILURE, 2008, 30 (10) : 959 - 964
  • [45] Determinants of Vancomycin Trough Concentration in Patients Receiving Continuous Veno-Venous Hemodialysis
    Quinn, Nicholas J.
    Sacha, Gretchen L.
    Wanek, Matthew R.
    Yerke, Jason
    Srinivas, Pavithra
    Hohlfelder, Benjamin
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (10) : 1133 - 1138
  • [46] Myoglobin clearance with continuous veno-venous hemodialysis using high cutoff dialyzer versus continuous veno-venous hemodiafiltration using high-flux dialyzer: a prospective randomized controlled trial
    Weidhase, Lorenz
    de Fallois, Jonathan
    Haussig, Elena
    Kaiser, Thorsten
    Mende, Meinhard
    Petros, Sirak
    CRITICAL CARE, 2020, 24 (01)
  • [47] Comparative polymyxin B pharmacokinetics in critically ill patients with renal insufficiency and in continuous veno-venous hemodialysis
    Yury A. Surovoy
    Maksim A. Burkin
    Inna A. Galvidis
    Mikhail A. Sobolev
    Onur Can Rende
    Sergei V. Tsarenko
    European Journal of Clinical Pharmacology, 2023, 79 : 79 - 87
  • [48] Comparative polymyxin B pharmacokinetics in critically ill patients with renal insufficiency and in continuous veno-venous hemodialysis
    Surovoy, Yury A.
    Burkin, Maksim A.
    Galvidis, Inna A.
    Sobolev, Mikhail A.
    Rende, Onur Can
    Tsarenko, Sergei, V
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (01) : 79 - 87
  • [49] Evaluation of acid-base control, electrolyte balance, and filter patency of a Prismaflexbased regional citrate anticoagulation protocol for pre-dilution continuous veno-venous hemodiafiltration
    Khadzhynov, Dmytro
    Slowinski, Torsten
    Lieker, Ina
    Neumayer, Hans-H.
    Peters, Harm
    CLINICAL NEPHROLOGY, 2014, 81 (05) : 320 - 330
  • [50] Use of Continuous Veno-Venous Hemodialysis (CVVHD) in Treatment of a Polytrauma Patient with Severe Hemophilia A
    Zajaczkowska, Renata
    Zorska, Joanna
    Serednicki, Wojciech
    Wrzosek, Anna
    Wordliczek, Jerzy W.
    AMERICAN JOURNAL OF CASE REPORTS, 2022, 23